Prof. Charlie Gourley
Medical Oncologist
- CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Research
United Kingdom
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
Programmes developed by Prof. Charlie Gourley
Oncology
PARP inhibition and DNA Damage Response (DDR)
This comprehensive resource looks at PARP inhibition and DDR as therapeutic targets across multiple tumour types
Experts
Prof. Simon Boulton, Dr Violeta Serra, Dr Judith Balmaña, Prof. Charlie Gourley-
30 MIN
-
Oct 2021
Oncology
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
Experts
Dr Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr Mark J. O'Connor, Prof. Charlie Gourley, Dr Judith Balmaña, Prof. Sibylle Loibl-
Downloadable
Resources -
MIN
-
Sep 2021
Publication
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann-
Downloadable
Resources -
10 MIN
-
Sep 2021
Oncology
An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition
Experts
Prof. Keiichi Fujiwara, Prof. Simon Boulton, Dr Shinji Ohno, Dr Rebecca Dent, Prof. Charlie Gourley-
Downloadable
Resources -
60 MIN
-
Sep 2021